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The systems biology approach to complex diseases recognises that a potentially large number of bio-
chemical network elements may be involved in disease progression, especially where positive feedback
loops can be identiﬁed. Most of these network elements will be encoded by genes, for which different
alleles may affect the network(s) differentially. A primary requirement is therefore to determine the
relevant gene-network relationships. A corollary of this is that identiﬁcation of the network should
thereby allow one to ‘explain’ or account for any genetic associations.
We apply this approach to Parkinson’s disease, a disease characterised by apoptotic death of neurons of
the substantia nigra, and coupled signiﬁcantly to a derangement of iron metabolism. We thereby account
for the involvement of various genes and biochemical pathways associated with Parkinsonism, including
seemingly unconnected ones involving iron, a-synuclein, parkin, mitochondrial respiration and biology,
ceramide production, lysosome biology, Lewy body formation, and so on. Although such an analysis nec-
essarily recognises that there is no unitary ‘cause’ of Parkinson’s, it also recognises that each of the ele-
ments contributing can or does effectively converge on a particular mode of apoptotic cell death in
dopaminergic neurons, often involving iron-mediated hydroxyl radical formation.
Overall, the systems biology approach allows us to propose at least one coherent synthesis of the rather
disparate literature surrounding the aetiology of Parkinson’s disease, and thereby to suggest some (syn-
ergistic) targets for ameliorating the disease and its progression.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction factors (Jellinger, 2012; Winklhofer and Haass, 2010) At the cellu-As with all traits, especially if the phenotype is heterogenous
and ambiguous (Yang et al., 2010), sporadic idiopathic Parkinson’s
disease (PD) (OMIM entry #168600) is recognised as a complex
multifactorial disease, most likely with a variety of subforms with
variable contributions of genetic susceptibility and environmentalisease; SN, substantia nigra;
ive element/iron responsive
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Y-NC-ND license.lar level the main manifestation responsible for the disease-
characterizing motor features is a progressive degeneration and
loss of preferential dopaminergic neurons containing neuromela-
nin in the substantia nigra (SN) (Gibb, 1992; Kastner et al., 1992)
and the production of intracytoplasmic inclusions of protein/lipid
aggregates called Lewy bodies (LB). At the clinical or physiological
level the disease is characterised by a variety of motor (bradykine-
sia, rigidity, tremor, postural instability) and non-motor symptoms
(hyposmia, autonomic dysfunction, REM sleep behaviour disorder,
depression, cognitive decline and others) (Chaudhuri and Schapira,
2009; Maetzler et al., 2009; Singh et al., 2007).
Given that the existence of neurodegeneration in PD is not in
doubt, and that it affects many parts of the central and peripheral
nervous system (Braak et al., 2003; Wakabayashi et al., 2010), the
main questions to be asked are
(i) Why is neurodegeneration especially prevalent and harmful
in the substantia nigra?, and
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Although, by deﬁnition, PD shares neurodegenerative proper-
ties with other neurodegenerative diseases such as Alzheimer’s,
Huntington’s and Friedreich’s Ataxia, we shall seek here to conﬁne
our attention mainly to PD.
Until recently the vast majority of PD cases have been regarded
as sporadic (90–95%), and familial cases were attributed to only 5–
10% (Jomova et al., 2010a). However, this view reﬂects only part of
the genetic input to the disease. Due to new, high-throughput tech-
nologies our knowledge of the genetic contribution to PD is
increasing rapidly. As with many other disorders (Manolio et al.,
2009), the genetic underpinnings of this neurodegenerative disor-
der are no longer seen only in a mono-causal or Mendelian way, as
so far known from the monogenic forms of PD in which rare vari-
ants account only for a small overall effect or frequency of cases.
Rather, low-frequency variants with intermediate effects (for
example GBA mutations) or common variants as implicated by
GWAS studies (loci include for example SNCA and MAPT) (Nalls
et al., 2011) lead to a different (and improved) understanding of
the pathophysiology of the disease. However, the inﬂuence of
low-frequency and common variants to the ﬁnal onset of PD is less
penetrant and, more importantly, probably quite distinctly inﬂu-
enced by other genetic, environmental (McCulloch et al., 2008)
and possibly further factors. Hence, for the understanding of path-
ophysiological pathways it is still wise ﬁrst to consider monogenic
forms, in which speciﬁc cascades can be followed more easily.
Therefore, with regard to PD, we will focus in the following on
the genes known to be involved in monogenic forms of PD, usually
referred to as PARK genes, which are listed in Table 1.
However, there is an additional crucial factor for which there is
no direct genetic basis, and that is the metal iron (in various
forms). A very large literature [e.g. (Barnham and Bush, 2008;
Boelmans et al., 2012; Bolognin et al., 2009b; Crichton et al.,
2011; Dexter et al., 1989; Galazka-Friedman et al., 2012; Jomova
et al., 2010a; Kell, 2009b, 2010b; Mochizuki and Yasuda, 2012;
Nunez et al., 2012; Perez et al., 2008; Rhodes and Ritz, 2008;
Schneider and Bhatia, 2012; Schneider et al., 2012; Sian-Hulsmann
et al., 2011, 2010; Snyder and Connor, 2009; Thompson et al.,
2001; Zecca et al., 2004)] strongly indicates that the metal iron,
when unliganded and in various ionic forms, is intimately (Dröge,
2002) involved in the aetiology of PD, albeit that the molecular
mechanisms and the degree of this contribution still need to be
elucidated in detail.
The chief underlying basis for this is that hydrogen peroxide
and superoxide are both produced by mitochondria in very large
amounts [e.g. (Adam-Vizi, 2005; Adam-Vizi and Chinopoulos,
2006; Barja, 1999; Fato et al., 2008a; Orrenius et al., 2007; Raha
and Robinson, 2001; Turrens, 2003)], and can react with iron when
it is in unliganded or poorly liganded forms. The chemistry of the
Fenton (Wardman and Candeias, 1996) (Eq. (1)) and Haber–Weiss
(Kehrer, 2000) (Eq. (2)) reactions is as follows:
FeðIIÞ þH2O2 ! FeðIIIÞ þ OH þ OH ð1ÞO2 þ FeðIIIÞ ! O2 þ FeðIIÞ ð2Þ
Together they allow iron to act catalytically to produce hydro-
xyl radicals (OH), the most damaging of the reactive oxygen spe-
cies (Halliwell and Gutteridge, 2006) as they can react in
nanoseconds with essentially any molecules to which they are
adjacent. Additionally, reactive nitrogen species can be formed by
reactions involving NO, to produce the similarly very reactive per-
oxynitryl radical (Ebadi et al., 2005b; Ebadi and Sharma, 2006; Kell,
2009b, 2010b). We use the term ‘iron’ to mean iron of any valency
or degree of liganding unless speciﬁed.Iron content in the most vulnerable brain region of PD, the SN, is
higher than in most other regions of the brain, even under physio-
logical conditions (Hallgren and Sourander, 1958; Riederer et al.,
1989). The process of neurodegeneration may thus be accelerated
by increased levels of iron, especially Fe(II) reacting with H2O2 to
form OH via the Fenton reaction and favouring a greater turnover
of the Haber–Weiss cycle which leads to an ampliﬁcation of oxida-
tive stress (Gerlach et al., 1994; Riederer and Youdim, 1993) with
subsequent cell death (Youdim et al., 1991). Iron can also react
with dopamine directly in the dopaminergic neurons of the SN to
form a toxic complex (Arreguin et al., 2009; Paris et al., 2005) that
itself probably catalyses hydroxyl formation. The general abun-
dance of iron in the SN is probably sufﬁcient to account for the
selectivity of neurodegeneration, i.e. the ﬁrst question. Addition-
ally, neuromelanin, also especially localised in the dopaminergic
neurons of the SN, is known to be an excellent binder of metal ions,
in particular iron, thereby contributing to the iron load of the SN
(Ben-Shachar et al., 1991).
The selective increase of total iron content and iron(III) in the
SN of PD patients has been demonstrated both biochemically and
histochemically (Dexter et al., 1989; Riederer et al., 1989, 1992;
Soﬁc et al., 1988, 1991). Moreover, increased iron levels of the SN
in PD have also been demonstrated in vivo using magnetic reso-
nance imaging (MRI) (Martin, 2009; Rossi et al., 2010; Zhang
et al., 2010) and transcranial sonography (TCS) (Becker et al.,
1995; Berg et al., 2001, 2002; Götz et al., 2004; Walter et al., 2002).
Importantly, in PD animal models, chelation of iron has been
shown to be effective in delaying or preventing neurodegeneration
by reducing the amount of iron which contributes to oxidative
stress (Kaur et al., 2003), indicating possible therapeutic strategies
(Jomova and Valko, 2011a; Van der Schyf et al., 2006; Whitnall and
Richardson, 2006).
The term ‘systems biology’ describes an approach to under-
standing biology that places emphasis on the interactions between
the components known via molecular biology, rather than on the
components themselves (Hood, 2003; Ideker et al., 2001; Kitano,
2002).
Because there are so many genes that are known to have a po-
tential contribution to PD in any individual case (e.g. (Antony et al.,
2011; Houlden and Singleton, 2012), such problems are properly to
be seen as problems of systems biology (Kell and Knowles, 2006;
Kell, 2009b, 2010b) for which a suitably annotated network model
may be used to encapsulate our understanding (Herrgård et al.,
2008; Kell, 2007; Kell and Mendes, 2008). The systems or network
view explains straightforwardly the complexity of the system and
how so many genes (or biochemical network elements) can be
operative in the same pathological process, and whether they are
‘upstream’ or ‘downstream’ in a particular cascade or network.
For instance, if we require sources of unliganded iron and of
(su)peroxide to produce hydroxyl radicals, then anything that
can increase one or more of these will appear to be (and will be)
a contributing causative factor of PD. The ﬁrst step, then, is to ﬁnd
out who the actors are and how they interact (Herrgård et al.,
2008; Kell and Knowles, 2006). We note in particular here the exis-
tence of two very useful systems biology models of iron metabo-
lism (Hower et al. 2009; Chifman et al. 2012).
The logic underpinning such an analysis could be as follows:
1. Both genetic and non-genetic factors inﬂuence the develop-
ment of PD. Despite so-called ‘monogenic’ forms, no one step
alone explains the entire system, and ‘iron’ is a noteworthy
non-genetic factor.
2. When we know the full biochemical network(s) involved,
and thereby the systems biology of disease progression, we
ought to be able to explain ‘a lot’, or at least the major
Table 1
Known genes and loci of familial and sporadic cases of PD.
Locus Gene Chromosome Gene product Inheritance Cellular or phenotypic
effects of mutations
Known molecular interaction
with iron?
PARK1 SNCA 4q21–23 a-Synuclein (pointmutation) AD Nigral degeneration with
Lewy bodies
Yes, several, including binding
PARK2 Parkin 6q25.2–27 E3 ubiquitin protein ligase AR Nigral degeneration
without Lewy bodies
Indirect via regulation of
DMT1
PARK3 Unknown 2p13 ? AD Nigral degeneration with
Lewy bodies
?
PARK4 SNCA 4p14–16.3 a-Synuclein (duplication or triplication) AD Nigral degeneration with
Lewy bodies
Yes, several, including binding
PARK5 UCHL1 4p14 Ubiquitin carboxyterminal hydrolase L1 AD No known pathology ?
PARK6 PINK1 1p35–36 PTEN-induced mitochondrial serine/
threonine kinase
AR Nigral degeneration with
Lewy bodies
Not as yet
PARK7 DJ-1 1p36 Redox-dependent molecular chaperone in
mitochondria
AR No pathology reported Not as yet
PARK8 LRRK2 12p11.2-q13.1 Leucine-rich repeat-containing kinase AD Variable a-synuclein and
tau pathology
Not in detail (possibly indirect
via interaction with Parkin)
PARK9 ATP13A2 1p36 Neuronal P-type ATPase AR Pallidopyramidal
degeneration
Not as yet
PARK10 Unknown 1p32 ? ? No pathology reported ?
PARK11 GIGYF2 2q36–37 Regulation of tyrosine kinase receptor
signalling?
AD No pathology reported ?
PARK12 Unknown Xq21–25 ? X-linked No pathology reported ?
PARK13 Omi/
HTRA2
2p12 Mitochondrial serine protease sporadic No pathology reported None direct
PARK14 PLA2G6 22q13.1 Phospholipase A2 AR Spheroid body
accumulation, Lewy body
formation
Not as yet.
PARK15 FBXO7 22q12–13 E3 ubiquitin protein ligase ? Parkinsonism and
pyramidal tract signs
?
PARK16 Unknown 1q32 ? ? ? ?
PARK17 VPS35 16q12 Vacuolar protein sorting 35 AD No pathology reported Not as yet.
PARK18 EIF4G1 3q26-q28 Eukaryotic translation initiation factor 4
gamma 1
AD a-Synuclein type Not as yet.
GBA 1q21 Lysosomal glucocerebrosidase sporadic Nigral degeneration with
Lewy bodies
Not as yet.
DMT1
(SLC11A2)
12q13 Proton-coupled divalent metal ion
transporter (solute carrier family 11,
member 2)
SCARB2 Position 77418010
in NCBI build 36.3
Lysosomal integral membrane protein type
2 (LIMP-2); trafﬁcking of GBA to lysosome
? ? ?
SREBF1/
RAI1
Position 17655826
in NCBI Build 36.3
? ? ? ?
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data (in that the pertinent genes should encode for or inﬂu-
ence the relevant biochemical networks).
3. A detailed survey of the literature illustrates the (numerous)
main processes involved in the (apoptotic) cell death charac-
teristic of SN neurones in PD. Here, we seek to include all
main processes known to us.
4. Consequently, the (systems biology) model that we provide
can give a reasonable explanation of the (partial) contribu-
tion of the various genes that have been identiﬁed to be
involved in the progression of PD and where appropriate in
their interaction with iron.
As mentioned above, so-called monogenic forms of PD are of
importance as they allow one to study the effects of a particularly
pathogenic mutation or allele and to model its contribution to the
pathogenesis of the progressive neurodegenerative process. Nota-
bly, indices of increased iron content are present not only in spo-
radic PD, but also in monogenic variants of PD (Schweitzer et al.,
2007b). Knowledge about the interaction of the pathways affected
in monogenic PD may therefore contribute to the understanding of
the role of iron in the pathogenesis of PD. Recently, Lv et.al indi-
cated that increased iron levels in chronic 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-treated PD mice correlate with theselective nigral dopaminergic neuron degeneration in Parkinson‘s
disease (Lv et al., 2011). Given that inhibition of complex I and iron
accumulation are important aspects of idiopathic PD, one study
from the group of Nunez may be of relevance for a better under-
standing of the pathophysiology. They analyzed iron-sulfur (Fe–S)
clusters as small inorganic cofactors present in numerous proteins.
These clusters are synthesized in the mitochondria and are in-
volved in many biological processes. By artiﬁcial inhibition of com-
plex I the group of Nunez found a reduction in cytoplasmic
aconitase activity associated with an increase in iron regulatory
protein (IRP) mRNA binding activity. Additionally, the cytoplasmic
labile iron pool was also elevated (Mena et al., 2011). They there-
fore hypothesise that Fe–S cluster inhibition could result in a false
iron deﬁciency signal as it is known that IRP activity regulates the
expression of iron import in a post-transcriptional manner.
Moreover, there are several iron-accumulating disorders that
primarily affect the basal ganglia leading to a phenotype domi-
nated by extrapyramidal symptoms including parkinsonism. As
in some of these disorders speciﬁc mutations and consecutively af-
fected pathways are also known, these disorders constitute an-
other interesting group that may help in the understanding of
the pathogenic role of iron in parkinsonism.
In the following we shall therefore seek to combine knowledge
derived from genetic studies and from pathological cascades
640 C. Funke et al. / Neurochemistry International 62 (2013) 637–652induced by iron in a systems biological approach to account for the
complexity of the pathogenesis of PD, at least in part.
2. Positive feedback and autocatalysis in cell death
In general terms, evolution has selected the topologies of bio-
chemical networks for robustness, since any single-point-failure
of the system is likely to be selected against [e.g. (Bornholdt and
Sneppen, 2000; Kitano, 2004; Shinar and Feinberg, 2010; Stelling
et al., 2004; van Nimwegen et al., 1999; von Dassow et al., 2000;
Wagner, 2005)]. There are at least two consequences:
 The ﬁrst is that in order to drive a cell towards death often
quite overwhelming stresses have to be applied, acting at
multiple points. This is also why multiple reactions have to
be affected to raise biochemical ﬂuxes for increasing the rate
of production of substances of interest in biotechnology, as
in (Butelli et al., 2008; Park et al., 2007), and why the most
effective pharmaceutical drugs (have to) act at multiple
points (Besnard et al., 2012; Hopkins et al., 2006; Hopkins,
2008; Lehár et al., 2007; Lehár et al., 2008; Small et al., 2011).
 The second consequence is that one means by which to have
major effects on a biochemical network is to have a positive
feedback such that a toxin, for example unliganded iron or
the hydroxyl radical, reacts with the system to cause yet fur-
ther production of unliganded iron or the hydroxyl radical,
and so on. This runaway kind of reaction is clearly capable
of overwhelming any kinds of robust defences (Kell, 2010b).
A particularly nice example involving unliganded iron and hy-
droxyl radical provides exactly the explanation of why bactericidal
antibiotics differ mechanistically from those that are merely bacte-
riostatic (Dwyer et al., 2009; Kell, 2010b; Kohanski et al., 2007).
In the present article we shall bring together the evidence that
there is an autocatalytic interplay between biochemical events in
the lysosome and in mitochondria that lie at the heart of the neu-
rodegeneration occurring in Parkinson’s disease. Cocktails of sub-
stances affecting multiple relevant targets may thus offer the
best therapeutic options. A ‘mind map’ of the review is given at
Fig. 1, and the relevant literature review extends to June 2012.
3. Mechanisms of cell death
To answer the second question above, the mechanisms of neu-
ronal cell death accompanying Parkinson’s, requires recognition
that cells tend to die either by necrosis or by apoptosis (Kostrzewa,
2000), and there is considerable evidence that neuronal cell death
during PD is essentially apoptotic in nature [e.g. (Blum et al., 2001;
Burke, 2007; France-Lanord et al., 1997b; Hartley et al., 1994;
Jenner and Olanow, 2006; Lev et al., 2003; Maruyama et al.,Fig. 1. A ‘mind map’ summarising the various sections in the re2002; Novikova et al., 2006; Petit et al., 2005; Shi et al., 2010;
Tatton et al., 2003; Vila and Perier, 2008; Vila et al., 2008; Xu
et al., 2005b; Yacoubian and Standaert, 2009; Yasuda and
Mochizuki, 2010; Zhu et al., 2010)]. This is not necessarily surpris-
ing in view of the extensive evidence for mitochondrial dysfunc-
tion in PD, that we shall come to.4. Apoptosis, mitochondria, lysosomes and ‘ceramide’
In apoptosis (Kerr et al., 1972) (Fig. 2), the best known version
of ‘programmed cell death’ (Burke, 2007), cells exposed to various
stresses, such as oxidative stress mediated by inﬂammatory cyto-
kines, undergo a regulated demise involving the release of cyto-
chrome c from mitochondria and the activation of various
proteases (caspases) that cause cellular degradation. A variety of
toxins that cause mitochondrial dysregulation can also thereby
affect Parkinson-like syndromes.
One mechanism contributing to oxidative stress in PD involves
an impairment of mitochondrial function, especially of complex I
activity (Bové et al., 2005; Danielson et al., 2011; Dawson and
Dawson, 2003; Fato et al., 2008b; Henchcliffe and Beal, 2008;
Perier et al., 2007; Schapira et al., 1989; Schapira, 2007; Sterky
et al., 2012; Winklhofer and Haass, 2010), increased excitotoxicity,
altered calcium homeostasis (Lang, 2007; Maetzler et al., 2007) and
other factors. The involvement of aberrant complex I activity is
especially interesting, as both rotenone and MPTP+, inhibitors of
complex I, can induce Parkinson-like symptoms [e.g. (Drechsel
and Patel, 2008; Miller et al., 2009; Sherer et al., 2002; Sterky
et al., 2012; Terzioglu and Galter, 2008)]. It is of interest that
rotenone can also lead to selective uncoupling in complex I
(Phillips and Kell, 1982), with presumed increased scope for
(su)peroxide production. ROSs can also be induced by the
interaction of inhibitors with complex III [e.g. (Therade-Matharan
et al., 2005)].
A particularly interesting relationship here is that between ‘cer-
amide’ and mitochondria-induced apoptosis. Ceramide is a generic
term used to describe a sphingolipid [see (Heavner et al., 2012) for
the relevant biochemical networks] composed of sphingosine
amide linked by N-acylation to a fatty acid. Thus C16-ceramide, a
typical ceramide found in mammalian cells, involves a fatty acyl
chain with 16 carbons (palmitate). What has become clear over
some 20 years [e.g. (Birbes et al., 2002; Colombini, 2010; Degli
Esposti and McLennan, 1998; France-Lanord et al., 1997a; Jana
et al., 2009; Levenson et al., 2004b; Siskind, 2005)] is that while
such ceramides cannot themselves cross cell membranes, they
are capable of effecting pore formation in the mitochondrial outer
membrane, thereby allowing cytochrome c to diffuse into the cyto-
plasm, and of interacting with the mitochondrial respiratory chain
(Di Paola et al., 2000). Both of these activities thus contribute to the
induction of apoptosis.view. To read this start at ‘‘12 o’clock’’ and read clockwise.
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induction of apoptosis in dopaminergic neurons of the SN.
Lysosomes also play an important role and free iron in lyso-
somes and permeabilization of lysosomal membranes are an
important inducer of oxidative stress (Dusek et al., 2012). They in-
duce ferritin with concomitant mitochondrial damage (Ghosh
et al., 2011) and ultimately apoptosis. Lysosomes thereby contrib-
ute directly to neurodegeneration by the ectopic release of lyso-
somal proteases into the cytoplasm. Lysosomal breakdown and
AP accumulation also occurred in PD brain samples, where LB were
strongly immunoreactive for AP markers (Dehay et al., 2010). Cells
prevent apoptosis by binding reactive iron to heavy-chain (H)-fer-
ritin, which can incorporate lysosomal iron into ferritin molecules
(Persson, 2005).
In the following we shall review the existing knowledge of the
contribution of iron in different monogenic forms of PD and other
monogenic disorders accumulating iron in the basal ganglia with a
clinical presentation that includes Parkinsonism. We begin with
the syndromes of neurodegeneration with brain iron accumulation
(NBIA) (Schneider et al., 2012), for which the link to iron metabo-
lism is rather overt, followed by the more clinically pure parkinso-
nian and other seemingly more complicated disorders. Our aim is
to understand better the ways in which iron affects different path-
ways that ﬁnally accumulate in the clinical picture of
Parkinsonism.5. Syndromes of neurodegeneration with brain iron
accumulation (NBIA): Complicated forms of Parkinsonism
bridging the gap to PD
5.1. PLA2G6-associated neurodegeneration (PARK14)
A group of disorders characterized by prominent iron accumu-
lation in the basal ganglia has been described, and referred to col-
lectively as syndromes of neurodegeneration with brain iron
accumulation. One of the core syndromes is, besides pantothenate
kinase-associated neurodegeneration, PLA2G6-associated neuro-
degeneration (PLAN) (Hayﬂick, 2003, 2006; McNeill, 2012; Schnei-
der et al., 2012). The PLA2G6 gene is located on chromosome 22;
the encoded protein, iPLA2 beta is a group VIA calcium-indepen-
dent phospholipase A2 and is an 85- to 88-kDa cytoplasmic PLA2
whose amino acid sequence includes eight N-terminal ankyrin re-
peats, a caspase-3 cleavage site, relevant to the apoptotic mecha-
nism – see above, an ATP-binding domain, a serine lipase
consensus sequence (GXSXG), a bipartite nuclear localization se-
quence, and a C-terminal calmodulin-binding domain (Ma and
Turk, 2001). iPLA2 beta hydrolyzes the sn-2 acyl chain of phospho-
lipids, generating free fatty acids and lysophospholipids and is sug-
gested to play important roles in remodeling of membrane
phospholipids, signal transduction, cell proliferation, and
apoptosis.
The clinical phenotype associated with PLA2G6 mutations is
variable. On the one hand it may present as infantile neuroaxonal
dystrophy (INAD) or, on the other hand, when onset is later, with
complicated dystonia parkinsonism (Schneider and Bhatia,
2010a). In the adult-onset cases, parkinsonism was characterized
by the presence of tremor including a pill-rolling rest component,
rigidity, and severe bradykinesia with a good response to levodopa
(Paisan-Ruiz et al., 2009). However, there was early development
of dyskinesias. Cerebellar signs and sensory abnormalities which
are often prominent in the early childhood variant were absent. Re-
cently, Engel and colleagues (Engel et al., 2010) presented func-
tional studies correlating genetic alterations with the different
clinical presentations. They showed that mutations associated with
INAD/NBIA result in loss of enzyme activity, with mutant proteinsexhibiting less than 20% of the speciﬁc activity of the wild type
protein in both lysophospholipase and phospholipase assays,
which predicts accumulation of PLA2G6 phospholipid substrates.
In contrast, mutations associated with dystonia-parkinsonism did
not impair catalytic activity which may explain the relatively
milder phenotype and absence of iron accumulation in at least
some cases.
PLAN belongs to the group of neuroaxonal dystrophies, the
characteristic histological hallmark feature of which are spheroid
bodies (dystrophic neuroaxonal swellings) that are observed
throughout the peripheral and central nervous system. A core com-
ponent of neuroaxonal spheroids is tubulovesicular membrane
accumulation which may be explained by the role of PLA2G6 in
phospholipid homeostasis and may explain the axonal accumula-
tion of membranes in neuroaxonal spheroids (Engel et al.,
2010).The ﬁndings are in line with ﬁndings from animal studies
(Wada et al., 2009) where spheroids strongly stained ubiquitin po-
sitive in a mouse model (Malik et al., 2008).
Abnormal iron is found, in classical INAD, mainly in the globus
pallidus and sometimes, in the more atypical cases, in the SN
(Gregory et al., 2009; Paisán-Ruiz et al., 2010b). However, as men-
tioned above, genetically-proven cases without observable iron
deposition have been reported (Paisan-Ruiz et al., 2009). Wide-
spread presence of a-synuclein-positive LB pathology, which was
particularly severe in the neocortex has also been reported as rep-
resenting a link between PLA2G6 and parkinsonian disorders. The
LB pathology spread corresponded to Braak stage 6 and was that
of the ‘‘diffuse neocortical type’’ (Paisán-Ruiz et al., 2010b). In view
of the role of a synuclein in regulating fatty acid metabolism, Engel
et al. (2010) proposed that this may be the pathophysiological link
between PLA2G6 mutations and a-synuclein accumulation. A link
between fat metabolism and iron accumulation has also been ob-
served for a number of other, related disorders (Kell, 2009a).
Accumulation of hyperphosphorylated tau in both cellular pro-
cesses as threads and neuronal perikarya as pretangles and neuro-
ﬁbrillary tangles has also been reported (Paisán-Ruiz et al., 2010b).
Tau involvement tended to be less in late-onset cases (Kruer et al.,
2010; Schneider and Bhatia, 2010b).
The lysosome is the site of most labile iron in the cell [e.g. (Du-
sek et al., 2012; Fakih et al., 2008, 2009; Gorria et al., 2008; Kurz
et al., 2004, 2007, 2008a,b; Persson, 2005; Sahoo et al., 2012;
Tenopoulou et al., 2007; Terman et al., 2006; Yu et al., 2003)]. Thus
it is reasonable that lysosomal destabilization by impaired PLA2G6
activity might results in iron release inducing apoptotic processes.
5.2. ATP13A2 (PARK9) – Kufor Rakeb syndrome
Mutations in the neuronal P-type ATPase gene cause an autoso-
mal recessive form of early-onset, often complicated form of par-
kinsonism (Dusek et al., 2012; Ramirez et al., 2006). Recently,
Schneider et al. (Schneider et al., 2010; Schneider and Bhatia,
2012) reported the presence of iron accumulation in the putamen
and caudate nuclei as demonstrated by T2⁄-weighted MRI in a
Pakistani patient homozygous for a novel ATP13A2 mutation
(Paisán-Ruiz et al., 2010a). Similarly, in a Chilean family with
genetically-proven Kufor Rakeb syndrome (KRS) one of the com-
pound heterozygous mutation carriers showed iron deposition in
the basal ganglia in addition to severe global brain atrophy
(Brüggemann et al., 2010). How far the SN is also affected by the
iron accumulation remains as yet unclear.
In contrast to other forms of PD, one study reported a lack of
hyperechogenicity in the SN (which is thought to be a sign for in-
creased SN iron content (Brüggemann et al., 2010). This may argue
for a different underlying pathophysiology compared with other
monogenic forms of parkinsonism and idiopathic PD. Kufor-Rakeb
syndrome belongs to the syndromes of neurodegeneration
Fig. 2. Interactions between mitochondria, lysosomes, iron and apopotosis in the systems biology of Parkinson’s disease. The ﬁgure illustrates much of what we know about
the aetiology of Parkinson’s disease, showing in particularly the interplay between mitochondria and lysosomes during the apoptotic cell death that characterises the death of
neurons in the substantia nigra that is the hallmark of PD. The role and location in the network of a variety of gene products known to be involved in PD neurodegeneration is
also illustrated. Because the nature of many of the interactions is still not known we have decided not to use the Systems Biology Graphical Notation for these (Le Novère
et al., 2009).
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Schneider et al., 2010) and classiﬁcation of KRS as NBIA type 3
has been proposed (Schneider et al., 2010).
The 26 kb-spanning gene contains 29 exons and encodes a lyso-
somal 5 P-type ATPase. While postmortem studies of human KuforRakeb disease are lacking, nerve biopsy revealed cytoplasmic
membrane-bound, irregular, and occasionally folded inclusions
within Schwann cells, perineurial and epineurial cells (Paisán-Ruiz
et al., 2010a). More recently, post-mortem pathological examina-
tion in patients with ATP13A2 mutations, clinically presenting
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and glial lipofuscinosis involving the cortex, basal nuclei, cerebel-
lum, but sparing the white matter, with whorled lamellar
inclusions typical of NCL in electron microscopy. Lipofuscin depos-
its were conﬁrmed in the retina (Bras et al., 2012).
Functional studies showedmutant ATP13A2 was retained in the
endoplasmic reticulum, and there was premature degradation by
the proteasomal, but not the lysosomal, pathways which may con-
tribute to the aetiology (Park et al., 2011). The exact molecular link
to iron remains unknown.5.3. Pantothenate kinase-associated neurodegeneration
Mutations in the PANK2 cause pantothenate kinase-associated
neurodegeneration, the most common cause of NBIA. There are
links to PLA2G6-associated neurodegeneration both clinically, on
imaging grounds and pathologically, in that both are characterized
by iron accumulation and are classiﬁed as neuroaxonal dystro-
phies. In PKAN, iron accumulation is present in the globus pallidus,
both as ferric iron (Fe3+; the paramagnetic form putatively associ-
ated with MRI hypointensity) but to a lesser degree also ferrous
iron (Kruer et al., 2011). Diffuse iron-staining of the neuropil (‘‘iron
dust’’) may be present. However, this NBIA syndrome is not classi-
ﬁed as a PARK disorder, nor considered a major cause of parkinson-
ism. Instead patients typically present with early onset dystonia
with pyramidal signs (Hayﬂick, 2003). Thus, for reasons of focus,
PKAN will not be further discussed here.6. Monogenic PD forms, in which interaction with iron has been
demonstrated
6.1. a-Synuclein (PARK1 and PARK4)
The ﬁrst gene product described to be associated with familial
PD was a-synuclein (Polymeropoulos et al., 1997), encoded by
the SNCA gene (Xia et al., 2001). Synucleins are proteins which oc-
cur abundantly in the brain (Goedert, 2001). Of these, a-synuclein
is a cytoplasmic lipid binding protein considered to be involved in
storage and regulation of neurotransmitters as well as in synaptic
vesicle recycling (Lotharius and Brundin, 2002; Vekrellis et al.,
2004). a-Synuclein is also the main component of LB, the classic
pathological intraneural inclusions in PD, and may itself be oxida-
tively modiﬁed (Double et al., 2008). LBs contain nearly 80 other
proteins (Licker et al., 2009), amongst others ubiquitin (Kuzuhara
et al., 1988), proteasome subunits (Ii et al., 1997), heat shock pro-
teins (Auluck et al., 2002) and neuroﬁlaments (Galvin et al., 1997).
LBs are found not only in idiopathic PD but also in most monogenic
forms of PD (Duda et al., 2002; Spillantini et al., 1998). In fact, LBs
are abundantly present in the SN where iron accumulation also oc-
curs (Li et al., 2010a; Spillantini et al., 1997). In addition, ferrous
(Fe(II)) and ferric iron (Fe(III)) are found to be present in LBs (Peng
et al., 2010b) as well as in many other amyloid structures (Das
et al., 2010; Singh et al., 2010). There seem to be different types
of interaction of a-synuclein and iron – all leading to increased
toxicity.
First, a possible interaction of iron and a-synuclein has been
demonstrated by treating SK-N-SH, a neuroblastoma cell line, cells
with different iron concentrations, which lead to ferric iron-
induced a-synuclein aggregation (Li et al., 2010a). More generally,
ferric iron may itself catalyse the formation of a-synuclein oligo-
mers (Brown, 2009; Hillmer et al., 2010; Peng et al., 2010b).
Second, it has been shown, that a-synuclein is especially vul-
nerable to changes in iron concentration as the 50-untranslated re-
gion of a-synuclein mRNA contains an element predicted to
represent an iron responsive element (IRE) (Friedlich et al.,2007). Therefore, it has been suggested that iron might regulate
a-synuclein aggregation via the iron responsive element/iron reg-
ulatory protein system (IRE/IRP).
Third, Li et al. observed an upregulation of the mRNA level of
a-synuclein as well as an increase of its aggregation in SK-N-SH
cells after previous knockdown of the IRP (Li et al., 2010b). This
overexpression in turn seems to not only have an effect on a-
synuclein aggregation but also on the toxicity of iron: Studies in
SK-N-SH neuroblastoma cells overexpressing the wildtype a-
synuclein have shown an enhanced toxic effect of ferric iron, a de-
crease in cell viability and mitochondrial membrane energisation
and an increase in intracellular ROS (He et al., 1996). Additionally,
by silencing the expression of a-synuclein, iron-induced toxicity
could be attenuated to some extent (He et al., 1996). According
to these ﬁndings, it seems likely that a-synuclein aggregation
may increase the toxicity of iron in SK-N-SH neuroblastoma cells.
Fourth, SH-SY5Y cells stably expressing the divalent metal ion
transporter 1 (DMT1) show a dramatic enhancement of Fe2+ uptake
into the cells. In combination with mutant A53T a-synuclein the
Fe2+-mediated toxicity was much more aggravated. Interestingly,
this phenomenon seems to occur as a result of excessive autopha-
gic activity and not because of an apoptotic process (Chew et al.,
2011).
Fifth, the group of Brown (Davies et al., 2011) provided evidence
that a-synuclein is able to function as a cellular ferrireductase,
reducing iron(III) to iron(II). By overexpressing a-synuclein in hu-
man neural cell lines, a signiﬁcant increase in ferrireductase activ-
ity and therefore in iron(II) concentration could be demonstrated
in comparison to cells normally expressing the protein. Moreover,
they suggest that iron binding of a-synuclein could be important
for the normal protein activity.
Sixth, there also seems to be a possible and interesting link be-
tween a-synuclein expression and mitochondrial dysfunction:
overexpression of wildtype a-synuclein has been shown to de-
crease mitochondrial complex I activity and led to increased ROS
production in human fetal dopaminergic primary neuronal cells
(Devi et al., 2008).
Finally, ﬁndings from cell-culture experiments are supported by
animal studies. Transgenic mice expressing the A53T mutation in
the a-synuclein gene and exposed to paraquat develop a progres-
sive age-related enhancement of dopaminergic neurodegeneration
after oral intake of increased amounts of iron in the neonatal per-
iod (Peng et al., 2010a).
6.2. Parkin (PARK2)
Mutations in the parkin gene cause autosomal recessive juve-
nile PD (Kitada et al., 1998). To date more than 100 pathogenic
mutations within the parkin gene have been identiﬁed resulting
in a loss of function (Hardy et al., 2009; Hardy, 2010; Nuytemans
et al., 2010). An inactivation of parkin is also thought to play a role
in sporadic PD (Pilsl and Winklhofer, 2012).
A decade ago the group of Hirsch identiﬁed via immunohisto-
chemical studies the expression of parkin in neuronal perikarya
and processes. Additionally, it was found in glial and blood vessels
in the human brain (Zarate-Lagunes et al., 2001). In the physiolog-
ical state, parkin has been proposed to have a wide neuroprotective
capacity (Winklhofer and Haass, 2010), amongst others protection
of cells against proteasome inhibition, mitochondrial dysfunction,
endoplasmic reticulum stress and excitotoxicity [for review see
(Moore, 2006; Winklhofer, 2007)]. Parkin functions as an E3 ubiq-
uitin ligase, which subsequently polyubiquitinates its protein sub-
strates, thus targeting them for degradation by the 26S
proteasomal complex (Moore, 2006).
An inactivation of parkin due to its misfolding as a consequence
of severe stress (oxidative, nitrosative or dopamine) has been
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LaVoie et al., 2005, 2007; Schlehe et al., 2008; Wang et al., 2005;
Winklhofer et al., 2003; Wong et al., 2007; Yao et al., 2004).
In brains of PD patients and animal disease models, parkin was
found to be S-nitrosylated. S-nitrosylated proteins show concomi-
tant effects on neurodegeneration (Gu et al., 2010). This alteration
evidently stimulates the E3 ligase activity of Parkin, which has
been hypothesized to lead to an autoubiquitination with subse-
quent inhibition of its activity (Lim et al., 2002; Lipton et al., 2005).
The interaction of Parkin with iron metabolism has also been
investigated. Parkin plays a key role (Roth et al., 2010) in the reg-
ulation of metal transport via proteasomal degradation of the 1B
isoforms of divalent metal ion transporter 1 (DMT1). The latter is
the major transport protein responsible for the uptake of iron into
mammalian cells and of iron exit from endosomes (Garrick et al.,
2012), and is also present in the brain (Salazar et al., 2008b). There
exist four major mRNA isoforms resulting in four protein isoforms,
1A versus 1B and +IRE versus IRE isoform. The ﬁrst 1A and 1B iso-
forms describe just the different transcription start points and the
+IRE/IRE isoforms reﬂect the presence or absence of an iron
responsive element in the 30 region of the mRNA. Consistent with
earlier experiments (Roth et al., 2010), the group of Garrick dem-
onstrated that the regulation of DMT1 by proteasomal degradation
due to parkin is isoform speciﬁc. While 1A DMT1 seems to be
unaffected by parkin, the 1B DMT1 isoform can be a target for
the E3-ligase (Garrick et al., 2012). Relevance to PD from these
ﬁndings can be derived from the fact that the group of Hirsch dem-
onstrated recently an increase in the expression of DMT1 in the SN
of PD patients (Salazar et al., 2008a). The effects of parkin muta-
tions on 1B isoforms ubiquitination have not yet been studied,
although further evidence for the importance of DMT1 is that a
mutation in DMT1 that impairs iron transport may be protective
in rodents against the parkinsonism-inducing neurotoxins MPTP
and 6-hydroxydopamine (6-OHDA) (Salazar et al., 2008a).
It is therefore tempting to speculate that changes in DMT1 reg-
ulation results in alterations of iron transport in speciﬁc brain re-
gions with possible subsequent enhancement of oxidative stress.
However, SNP analysis in the DMT1 gene in Han Chinese popula-
tion failed to ﬁnd any signiﬁcant association between the tested
genotypes, alleles or mutation and PD (He et al., 2011).
Besides the DMT1 regulation other lines of evidence indicate a
possibly important interaction of parkin and iron: experiments
with Drosophila also demonstrate an important function of parkin
in protection against redox-active metals and pesticides. Flies mu-
tant for parkin showed an extended lifespan through sequestration
of redox active metals and an enhancement of anti-oxidative path-
ways (Saini et al., 2010).
7. Monogenic forms associated with mitochondrial gene
products which act in the same pathway as parkin and for
which so far no direct interaction with iron has been shown
Because mitochondria are normally the main cellular source of
the less toxic (than OH) reactive oxygen species peroxide and
superoxide, anything that disrupts mitochondria could in principle
lead to an increase in (su)peroxide production. This in turn, if free
iron is available, can produce the hydroxyl radical and thereby
even liberate more iron from mitochondrial components such as
Fe–S centres (Kell, 2010a). In this sense, any role of iron in effecting
neurodegeneration might be anticipated to be rather secondary for
these mitochondrially acting gene products.
7.1. Pink1 (PARK6)
PINK1 (PTEN-induced putative kinase) encodes a mitochondrial
targeted serine/threonine kinase and is another cause of autosomalrecessive, early-onset Parkinsonism (Pilsl and Winklhofer, 2012;
Valente et al., 2004). It has been demonstrated that PINK1 and
Parkin act in a common molecular signalling pathway in which
Parkin acts downstream of PINK1 to protect mitochondrial integ-
rity. Both interact with components responsible for ﬁssion and fu-
sion of the mitochondria (Clark et al., 2006; Park et al., 2006; Poole
et al., 2008; Yang et al., 2008). PINK1 is necessary for long term sur-
vival and mitochondrial function in human dopaminergic neurons
(Wood-Kaczmar et al., 2008). Silencing PINK1 in SH-SY5Y cells led
to an increase in mitochondrial dysfunction and oxidative stress
(Gegg et al., 2009; Vos et al., 2012).
No association of iron-induced oxidative stress and PINK1 func-
tion has been described so far, although patients carrying a PINK1
mutation displayed a signiﬁcantly larger area of SN echogenicity (a
marker for increased tissue iron content in PD) than did healthy
controls assessed with transcranial ultrasound (Schweitzer et al.,
2007a). Because of this indirect evidence, and due to the neuropro-
tective function of PINK1 and its mitochondrial localisation an
interaction with iron and subsequent enhancement of oxidative
stress may be anticipated and deserves further investigation, par-
ticularly with regard to detecting (su)peroxide production (Davey
and Kell, 1996), a possibility made more plausible by the recent
ﬁndings with vitamin K2 (Vos et al., 2012). PINK1 dysfunction does
lead to the production of Lewy bodies (Samaranch et al., 2010).7.2. Omi/HTRA2 (PARK13)
Omi/HTRA2 functions as a serine protease and contains an
N-terminal mitochondrial targeting sequence. Therefore it is also
linked to the group of proteins responsible for mitochondrial dys-
function and neurodegeneration (Strauss et al., 2005). Mutations in
the Omi/HTRA2 gene inactivate its protease activity and have been
identiﬁed as a high risk factor for the development of PD (Strauss
et al., 2005). HtrA2 interacts with PINK1 and both are components
of the same stress-sensing pathway. It is suggested that PINK1-
dependent phosphorylation of HtrA2 might modulate its proteo-
lytic activity, thereby contributing to an increased resistance of
cells to mitochondrial stress (Plun-Favreau et al., 2007). So far no
interaction of HtrA2 and iron has been shown, but because of its
mitochondrial localization and relationship to PINK1, similar con-
clusions apply.7.3. DJ-1 (PARK7)
DJ-1 mutations are less prevalent causes of autosomal reces-
sively inherited PD (Bonifati et al., 2003) than are PINK-1 muta-
tions. Physiologically, DJ-1 displays various functions: it is a
redox-dependent molecular chaperone with neuroprotective func-
tions and inhibits, amongst others, a-synuclein aggregate forma-
tion (Shendelman et al., 2004). Therefore, the oxidation state of
DJ-1 plays an important role, in view of its chaperone function
(Zhou et al., 2006). Moreover, it has been shown that cysteine
106 of DJ-1 is essential for its neuroprotective activity (Canet-
Avilés et al., 2004; Taira et al., 2004; Waak et al., 2009; Yokota
et al., 2003). Localization studies described DJ-1 in different com-
partments of the cell, including cytoplasm, mitochondria and also
the nucleus. Notably, under oxidative stress an enhancement of
the mitochondrial localization is observed (Lev et al., 2008; Li
et al., 2005; Miller et al., 2003). DJ-1 has also been found to be pres-
ent in LBs [for review see (Licker et al., 2009)]. Under conditions of
oxidative stress DJ-1 is converted into an acidic variant allowing a
reaction with ROS and favouring a localization in the mitochondria.
Speciﬁcally, this oxidation of a cysteine in position 106 of the DJ-1
peptide is necessary for mitochondrial targeting and protection
against oxidation-induced cell death (Canet-Avilés et al., 2004).
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chondrial homeostasis, evidenced by a loss of DJ-1 leading to
impairment of mitochondrial respiration, reduced mitochondrial
membrane energisation and an increase in intramitochondrial
reactive oxygen species (Krebiehl et al., 2010). DJ-1 is also known
to be protective against neuronal apoptosis (Xu et al., 2005a).
In spite of all this evidence for involvement in oxidative stress,
similar to PINK1 and Omi/HTRA2, no direct relationship between
iron metabolism and DJ-1 has been demonstrated, yet.
8. Other genes associated with PD with possible but so far not
demonstrated links to iron homeostasis
8.1. LRRK2 (PARK8)
A rather common cause of autosomal dominantly inherited
monogenic PD is represented by mutations in the LRRK2 gene
(PARK8), mapped to chromosome 12p11.2-q13.1, which are lo-
cated all over the coding sequence. The LRRK2 gene encodes a large
multidomain protein (280 kDa) containing an armadillo (ARM) do-
main, an ankyrin (ANK) domain, leucine-rich repeats (LRR), Ras of
complex proteins (ROC), C-terminal of ROC (COR), mitogen-
activated protein kinase kinase kinase (MAPKKK) and a WD40 re-
peat domain (Kumari and Tan, 2009; Shen, 2004; Zimprich et al.,
2004). It is expressed in many regions of the central nervous sys-
tem, e.g. cerebellum, spinal cord and also in the SN as well as in
other organs (Paisán-Ruíz et al., 2004; Zimprich et al., 2004). Local-
isation studies describe LRRK2 to be predominantly present in the
cytoplasm, but also existing in the mitochondrial outer membrane
(Smith et al., 2005; West et al., 2005), additionally associated with
the plasmamembrane, lipid rafts, synaptic vesicles, the Golgi appa-
ratus and a cytoskeleton protein microtubule (Biskup et al., 2006;
Hatano et al., 2007). Importantly, as reviewed by Ghandi et al.
(Gandhi et al., 2009), LRRK2 is suggested to be localised to LBs in
human PD brains.
Within the LRRK2 gene many variations (point mutations) of
unknown signiﬁcance have been identiﬁed in almost all domains
(Chung et al., 2011). At the moment eight proven pathogenic muta-
tions are known [reviewed in (Kumari and Tan, 2009)]. One com-
mon mutation, G2019S, can be found in both familial and
sporadic cases of PD (Di Fonzo et al., 2005; Gilks et al., 2005;
Nichols et al., 2005). This mutation is located within the kinase
domain and considered to be associated with increased kinase
activity (Greggio et al., 2006; Jaleel et al., 2007; West et al.,
2005). In SH-SY5Y cells and primary neurons derived from mouse,
neuronal degeneration and toxicity could be observed as a result of
this increased kinase activity of the mutant G2019S LRRK2 (Smith
et al., 2005, 2006). Inhibiting LRRK2 kinase activity may offer neu-
roprotection (Liu et al., 2011). Interestingly, LRRK2 (wildtype and
mutated) seem to interact with parkin as demonstrated (Smith
et al., 2005) in HEK cells. The RING2 domain of parkin seems to
be primarily responsible for this interaction with LRRK2. Because
of this interaction and the fact that parkin plays a key role (Roth
et al., 2010) in the regulation of metal transportation, an indirect
interaction of LRRK2 with iron homeostasis is at least feasible.
The mitochondrial ‘‘membrane potential’’, better described as
‘‘membrane energisation’’ (Kell, 1992), and the total intracellular
ATP levels have been shown to be decreased in G2019S mutation
carriers (Mortiboys et al., 2010). Additionally, the same group re-
vealed an elongation of the mitochondria in mutation carriers as
well as an increase in its interconnectivity. Summarising these re-
sults, ﬁbroblasts from mutation carriers for the G2019S mutation
displayed an impairment of its mitochondrial function and
morphology.
Another fact to mention is the age-dependency of penetrance of
the G2019S mutation. The international LRRK2 consortiumestimates the risk of PD for a person carrying the LRRK2 G2019S
mutation to be about 28% at the age of 59 years, 51% at 69 years,
and 74% at 79 years (Healy et al., 2008). Obviously for any individ-
ual this is a function of the rest of their ‘‘genetic make-up’’ and its
interaction with environmental (lifestyle) stimuli. This necessarily
begs the question of why (mechanistically) some very old carriers
remain free of disease.
To date, no studies showing direct interactions of LRRK2 with
iron seem to have been published. However, increased tissue iron
levels of the SN have also been demonstrated for LRRK2-associated
PD by transcranial sonography (Schweitzer et al., 2007a,b;
Brockmann et al., 2010), so it may be possible that Parkinson’s
disease resulting from a variation in the LRRK2 allele does have
an impact on the acceleration of neurodegeneration via increased
iron levels and concomitant oxidative stress. However, this interac-
tion may be less strong and detrimental than the one in idiopathic
PD (Schweitzer et al., 2007a).
8.2. Glucocerebrosidase (GBA)
So far, heterozygous GBA mutations are the most common ge-
netic risk factor for PD (Lesage and Brice, 2009; Nichols et al.,
2009). The human Glucocerebrosidase (GBA) gene is located on
chromosome 1q21 and encodes for a lysosomal enzyme, that
hydrolyses the beta-glycosidic linkage of glycosylceramides, which
are present in the plasma membrane of mammalian cells and orig-
inate from ceramides and glucose [reviewed in (Bras and Singleton,
2009)]. Mutations in the GBA gene cause a lysosomal storage dis-
order named Gaucher disease (with accumulation of glucocerebro-
side in lysosomes of mononuclear phagocytes (Grabowski, 2008). If
only one GBA allele is affected a strong association with Parkinson-
ism is found (combined odds ratio of 5.43 to 6.98 compared to con-
trols) (Bras and Singleton, 2009; Goker-Alpan et al., 2004;
Sidransky et al., 2009a,b).
Lwin et al. ﬁrst reported (Lwin et al., 2004) this increased prev-
alence of mutations in GBA among patients with Parkinson’s dis-
ease and a lot of studies have conﬁrmed and extended this
observation, e.g. (Aharon-Peretz et al., 2005; Clark et al., 2005,
2007; Eblan et al., 2006; Sato et al., 2005; Toft et al., 2006).
Interestingly, Ron et al. observed in cell culture experiments
that mutant GBA interacts with parkin (Ron et al., 2010). Addition-
ally, they demonstrated that parkin promotes the accumulation of
mutant GBA in aggresome like structures. The authors therefore
hypothesise an involvement of parkin in mutant GBA degradation,
leading to a time-dependent accumulation of its natural substrates.
Recently, overexpression of GBA mutants has been shown to be
able to raise human a-synuclein levels signiﬁcantly in both cell
culture and in vivo (Cullen et al., 2011) without alteration of the
GBA activity in a dose- and time-dependent manner.
Notably, in the autosomal recessive Gaucher disease (GD) a dys-
regulation in iron metabolism (Schiano et al., 1993; Stein et al.,
2010; Weisberger et al., 2004) is well established, with (for exam-
ple) an impressive elevation of serum ferritin in GD 1 (Stein et al.,
2010). It is highly signiﬁcant that the lysosome is the chief site of
labile iron in the cell. This raises the question whether heterozy-
gous GBA mutation carriers affected by Parkinsonism also show
imbalances in iron homeostasis.
It would thus be logical (Kell, 2010a) to seek (and expect to ﬁnd)
a direct association with iron-mediated neurodegeneration in this
form of PD, although none has as yet apparently been described.
8.3. FBXO7 (PARK15)
Mutations in the FBXO7 gene causing parkinsonism compli-
cated by pyramidal features have recently been reported in an Ira-
nian family with homozygous mutations (Shojaee et al., 2008).
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phenotype were subsequently also described (Di Fonzo et al.,
2009). The locus was assigned as the PARK15 locus.
FBXO7 has been characterized as a member of the FBXO family
and is a component of modular E3 ubiquitin protein ligases (see
also PARK2/ parkin) that play a role in phosphorylation-dependent
ubiquitination (Jin et al., 2004). There is yet no overt link to iron.
Finally, a recent and extensive genome-wide association study
(Do et al., 2011) has identiﬁed some novel genetic loci (including
SCARB2 and SREBF1/RAI1) associated with Parkinson’s disease,
but not yet accorded PARK gene status. We have included them
in Table 1.9. Discussion
There is accumulating evidence that PD is best seen as a multi-
factorial, systems biology problem. This may be one reason why
searches for unitary causes of PD have largely not been successful.
Nonetheless, a variety of causes may converge on a more or less
unitary mechanism (Kell, 2010b), which is certainly involved in
many cases, and that is the autocatalytic production of the hydro-
xyl radical and other related toxicants catalysed by unliganded
iron.
Not least from genome-wide association studies, a number of
PARK genes have clearly been identiﬁed via alleles that have ‘ex-
treme’ effects on function and thereby allow them to be observed
as a ‘monogenic’ contributor to one or more forms of PD.
Here we thus reviewed functions of the known genes and pro-
teins that are associated with Parkinsonism and Parkinson’s dis-
ease with regard to their link to iron metabolism, trying to
incorporate current understanding into a more holistic perspec-
tive. As shown above, knowledge about the role of iron in Parkin-
sonism ranges from a rather overt, even likely causative role to
cases with no known direct association at all. Between these ex-
tremes there are ‘monogenic’ forms of PD in which iron may play
a contributory role in the neurodegenerative process. This becomes
especially obvious in the regulation of a-synuclein aggregation via
an iron regulatory protein system and the fact that LBs, which are
one of the hallmark features of PD, contain a-synuclein and iron.
Therefore, iron may in the future, with further insights into this
ﬁeld, prove to be one of the key connecting links between the var-
ious forms of PD. Recently, Lei et al. published observations from
tau-knockout mice developing amongst others an iron accumula-
tion, loss of neurons in the SN and parkinsonism. By treating mice
with an oral iron chelator, clioquinol, these symptoms could be
prevented. These data suggest that there might be a contribution
of tau to the toxic neuronal iron accumulation in PD (Lei et al.,
2012).
However, despite the voluminous evidence that iron may dam-
age tissue either directly or by changing the cellular environment
so that it is more susceptible to toxins, it is also possible that iron
deposition is in part a consequence of axonal disruption (Stan-
kiewicz et al., 2007), as part of an autocatalytic feedback
mechanism.
The understanding of the role of iron has implications for the
development of therapies. It is thus interesting to follow the cur-
rent literature reporting results from trials with iron chelation
agents (Ward et al., 2012) as potential treatments for PD and re-
lated disorders, but also for example Alzheimer’s disease (AD).
The ﬁrst successful demonstration of the utility of iron chelators
in slowing the progression of AD is more than 20 years old (Crap-
per McLachlan et al., 1991)! While there have been some promis-
ing results in cell cultures [e.g. (Avramovich-Tirosh et al., 2007;
Chao et al., 2010; Gaeta et al., 2011; Mercer et al., 2005; Wu
et al., 2010; Xu et al., 2008)] and animal models (Adlard et al.,2008; Bolognin et al., 2009a; Bowern et al., 1984; Cheng et al.,
2008; Dexter et al., 2011; Ebadi et al., 2002, 2005a; Gal et al.,
2009; Kooncumchoo et al., 2006, 2012; Lan and Jiang, 1997; Levenson,
2003; Levenson et al., 2004a; Levites et al., 2001; Mounsey and
Teismann, 2012; Mu et al., 2011; Perez et al., 2008; Saini et al.,
2010; Shachar et al., 2004; Shi et al., 2010; Ward et al., 2012; Zhang
et al., 2005, 2012), a resurgence of pre-clinical and clinical trials in
humans is only just beginning to show positive results (Weinreb
et al., 2009) and there has not yet been a clear correlation between
a reduction of iron seen via neuroimaging and clinical beneﬁt or
the lack thereof. It should be noted that most chelators are not spe-
ciﬁc to a single metal (Hider et al., 2011), such that they may alter
the distribution of multiple metals in the brain with possible un-
known effects following long-term use (Gh Popescu and Nichol,
2010). There are also issues connected with getting such drugs to
their actual sites of action (Dobson and Kell, 2008; Kell et al.,
2011, 2012). Hopefully with further research into this area,
whether with dietary (often polyphenolic) or pharmacological che-
lators, the effectiveness of the chelators can be increased in the
near future, making them a secure and useful treatment option.
Further study of natural, polyphenolic, dietary iron chelators seems
especially warranted (Di Giovanni, 2009; di Matteo et al., 2009;
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oxidants (such as various cysteine derivatives (Napolitano et al.,
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might suggest that the combination of anti-oxidants and iron
chelators will prove especially effective.References
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